%A Liu Jingjing, Jin Caibao, Xu Xiuwen, Zhu Xiaojian, Meng Li. %T Myeloid-derived suppressor cells—immunotherapy targets in hematological malignancies %0 Journal Article %D 2017 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2017.04.020 %P 313-316 %V 44 %N 4 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10212.shtml} %8 2017-04-08 %X In recent years, the research hot in the field of solid tumor and blood tumor focuses on the myeloid-derived suppressor cells (MDSCs). In tumors, MDSCs not only exert immunosuppression by inhibiting T cell proliferation, destroying the functions of natural killer cells and recruiting regulatory T cells, but also play non-immunosuppression roles in the promotion of angiogenesis and tumor metastasis. All of these hinder the anti-tumor therapy, and particularly affect the curative effect, which are related with a poor clinical prognosis. MDSCs can be used as prognostic markers, which provide new targets for immunotherapy.